13 October 2022

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

NOTICE OF FULL YEAR RESULTS

Aptamer Group plc (AIM: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, will announce its full year results for the year ended 30 June 2022 on Tuesday 18 October 2022.

Aptamer Group's CEO, Arron Tolley, Interim CFO, Jenny Cutler and CTO, David Bunka, will be hosting an in-person meeting and webcast for sell-side analysts at 10.00am BST on 18 October 2022. To register your interest in attending, please email [email protected].

- ENDS -

For further information, please contact:

Aptamer Group plc

Dr Arron Tolley                                                                               +44 (0) 1904 56 7790

SPARK Advisory Partners Limited - Nominated Adviser  

Andrew Emmott / Adam Dawes                                                          +44 (0) 20 3368 3550

Liberum Capital Limited - Broker

Richard Lindley / Ben Cryer / Will Hall / Cara Murphy                        +44 (0) 20 3100 2000

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone                              +44 (0) 20 3709 5700

[email protected]

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145.0 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.